-
-
-
-
-
-
-
AMAG Pharmaceuticals Completes Sale of its Rights to Intrarosa® to Millicent Pharma for up to $125 Million
-
-
-
-
-
-
-
AMAG Pharma (AMAG) Reports Q4 Loss of $5.89/Share
-
-
-
-
-
-
-
FDA AdCom Votes to Pull AMAG Pharma's (AMAG) Makena from Market in Mixed Vote
-
-
-
-
-
-
-
AMAG Pharma (AMAG) Reports Q1 Loss of $3.54/Share
-
-
-
-
-
-
-
AMAG Pharmaceuticals Announces Preliminary 2018 Financial Results and Provides 2019 Financial Guidance
-
-
-
-
-
-
-
AMAG Pharma (AMAG) Reports Q1 Loss Per Share of $1.59, Raises FY Revenue Guidance
-
-
-
-
-
-
-
AMAG Pharmaceuticals Announces FDA Approval of Makena® (hydroxyprogesterone caproate injection) Subcutaneous Auto-Injector to Reduce the Risk of Preterm Birth in Certain At-Risk Women
-
1,168,522 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

